Skip to Content

Press Releases

Press Releases

Aug 09 2019
Intec Pharma Reports Second Quarter 2019 Financial Results and Business Update
JERUSALEM , Aug. 9, 2019 /PRNewswire/ --  Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three and six months ended June 30 , 2019.   Highlights of the second quarter 2019 and recent weeks include: Completed the qualification studies for the
Jul 22 2019
Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Conference Call to begin at 8:30 am ET JERUSALEM , July 22, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces top-line data from the Company's pivotal Phase 3 trial (the ACCORDANCE trial) evaluating the safety and efficacy of the Accordion Pill ®
Jul 01 2019
Intec Pharma Announces Publication of Article Reviewing Accordion Pill's Unique Gastric Retention Platform in Therapeutic Delivery
Peer-reviewed journal article highlights unique oral delivery platform's ability to enhance pharmacokinetic and therapeutic benefit for challenging drugs JERUSALEM , July 1, 2019 /PRNewswire/ --   Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announced that a review
Jun 25 2019
Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders
Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients JERUSALEM , June 25, 2019 /PRNewswire/ ---  Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announces that results from an earlier Phase 2 clinical
Jun 19 2019
Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders
JERUSALEM , June 19, 2019 /PRNewswire/ -- Intec Pharma Ltd.  (NASDAQ: NTEC) (" Intec " or "the Company") today announced that results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) were highlighted yesterday in a
May 28 2019
Intec Pharma to Participate at June Investment Conferences
JERUSALEM , May 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that Company management will participate at the following upcoming investment conferences in June.  Jefferies Global Healthcare Conference Date: June 4-7, 2019 Company
May 20 2019
Intec Pharma Granted European Patent
Strengthens Protection for Accordion Pill Platform JERUSALEM , May 20, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the European Patent Office has granted the Company European Patent No. 2997953 titled, "DELIVERY DEVICE FOR ORAL INTAKE OF
May 16 2019
Intec Pharma Announces Research Collaboration Agreement With Merck
NEW YORK , May 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces it has entered into an agreement with Merck, known as MSD outside the United States and Canada , to explore using the Accordion Pill ® (AP) platform for an undisclosed development
May 07 2019
Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update
JERUSALEM , May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces financial results for the three months ended March 31, 2019 and provides a corporate update.  Highlights of the first quarter 2019 and recent weeks include: Announced that the last
May 02 2019
Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders
JERUSALEM , May 2, 2019 /PRNewswire/  -- Intec Pharma Ltd. (NASDAQ: NTEC) (" Intec " or "the Company") today announces that the results from a pharmacokinetics (PK) study of the Accordion Pill™-Carbidopa/Levodopa (AP-CD/LD) 50/500 mg dosed three times per day (TID) was accepted for presentation in
Displaying 1 - 10 of 93